½ÃÀ庸°í¼­
»óǰÄÚµå
1729193

¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå : ±Ô¸ð ºÐ¼®(ºÎ¹®º°, ¼­ºñ½º Á¦°ø¾÷üº°, Áö¿ªº°) ¹× ¿¹Ãø(2022-2032³â)

Global Swine Lameness Diagnostic Market Size study, by Sector (Public, Private), Service Provider (Veterinary Hospital/Clinic Laboratories) and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀåÀº 2023³â ¾à 1¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³âºÎÅÍ 2032³â±îÁö 3.80% ÀÌ»óÀÇ ¿Ï¸¸ÇÑ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¾çµ·»ê¾÷ÀÌ »ý»ê¼º¿¡ ´ëÇÑ ¿ä±¸¿Í µ¿¹°º¹Áö¿¡ ´ëÇÑ ±â´ëÀÇ °íÁ¶¿¡ ÀÓÇϰí ÀÖ´Â °¡¿îµ¥, µÅÁö ÆÄÇà´Â °æÁ¦Àû¡¤À±¸®ÀûÀÎ ¹®Á¦·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ±×·¯¹Ç·Î Á¶±â Áø´Ü, Ä¡·á °èȹ, ±º °ü¸® ÃÖÀûÈ­¿¡´Â µÅÁö ÆÄÇà Áø´Ü µµ±¸°¡ ÇʼöÀûÀÔ´Ï´Ù.

Çö´ëÀÇ ¼öÀÇ Áø´Ü ÇÁ·ÎÅäÄÝÀº ±Þ¼ÓÈ÷ ÁøÈ­Çϰí ÀÖÀ¸¸ç, µÅÁö ºÐ¾ßµµ ¿¹¿Ü´Â ¾Æ´Õ´Ï´Ù. °¡¿îµ¥ Áø´Ü¼­ºñ½º´Â µ¿¹°º´¿øÀ̳ª Ŭ¸®´ÐÀÇ °Ë»ç½Ç°úÀÇ Á¦ÈÞ¿¡ ÀÇÇØ ÇÕ¸®È­µÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª ½ÃÀåÀÇ È®´ë´Â ¸î °¡Áö ¿î¿µ»óÀÇ º´¸ñ¿¡ ÀÇÇØ ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù. ¿µ¼¼ ³ó°¡¿¡ À־ÀÇ ÀÎÁöµµÀÇ ³·À½, ÆÄÇà °ËÁö ÇÁ·Î±×·¥ÀÇ Àϰü¼º ¾ø´Â ½Ç½Ã, ½Ç½Ã°£ ¸ð´ÏÅ͸µ ÀÎÇÁ¶óÀÇ ºÎÁ·(ƯÈ÷ ½ÅÈï °æÁ¦ ±¹°¡) µîÀÌ, ¼ºÀåÀÇ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´ÜÀý ÇÁ·ÎÅäÄÝÀÇ Ç¥ÁØÈ­°¡ Á¦ÇѵǾî ÀÖ´Â °Íµµ Áø´ÜÀÇ ÀçÇö¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù¸¸, ¾÷°è´Â À̵¿½Ä ¼öÀÇ»ç À¯´Ö, Áö¼ÓÀûÀÎ ±³À° Ä·ÆäÀÎ, Áø´ÜÀÇ ¸ð¹ü »ç·Ê¿¡ ´ëÇÑ ÀνÄÀ» ³ÐÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ¾çµÅÁö ¹ÐÁý Áö¿ª¿¡¼­ÀÇ ÆÄÀÏ·µ ÇÁ·Î±×·¥À» ÅëÇØ ÀÌ·¯ÇÑ Á¦¾à¿¡ ²ÙÁØÈ÷ ´ëÇ×Çϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ Áøº¸´Â ÀÌ Æ´»õ Áø´Ü ºÐ¾ß¿¡ »õ·Î¿î ¼û°áÀ» ºÒ¾î³Ö°í ÀÖ½À´Ï´Ù. º¸´Ù, Áö±Ý±îÁö ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇß´ø ½ÃÀå¿¡¼­µµ ¾×¼¼½º°¡ È®´ëµÇ¾î Áø´ÜÀÌ º¸´Ù Àú·ÅÇϰí È®Àå°¡´ÉÇÏ°Ô µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ƯÈ÷ ´ë±Ô¸ðÀÇ »ó¾÷ ³óÀå¿¡ À־, ¹ÝÀÀÀû Ä¡·áº¸´Ù ¿¹¹æÀûÀÎ ±ºÀÇ °Ç°­ °ü¸®¿¡ÀÇ ´Ü°èÀûÀÎ º¯È­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì´Â ÷´Ü ¼öÀÇÇÐÀû ÀÎÇÁ¶ó, °íµµ·Î Á¶Á÷È­µÈ µÅÁö°í±â »ý»ê»ê¾÷, µ¿¹°À§»ý¿¬±¸¿¡¼­ °ü¹ÎÀÇ °­·ÂÇÑ Çù·Â°ü°è¿¡ ÀÇÇØ ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µÅÁö°í±â ¼ö¿äÀÇ È®´ë, »ý»ê¼º¿¡ ¿¬µ¿ÇÏ´Â µ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, Áß±¹, Àεµ, º£Æ®³² µîÀÇ ³ª¶ó¿¡¼­ Á¤ºÎ°¡ Áö¿øÇÏ´Â µÅÁöº´ ´ëÃ¥ ÇÁ·Î±×·¥¿¡ ÃßÁøµÇ¾î ¿¹Ãø ±â°£ Áß¿¡ °¡Àå ºü¸¥ ÆäÀ̽º·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • ºÎ¹®º°(°ø°ø, ¹Î°£)
    • ¼­ºñ½º Á¦°ø¾÷üº°(µ¿¹°º´¿ø/Ŭ¸®´Ð °Ë»ç½Ç)
  • ÁÖ¿ä µ¿Çâ
  • °æ±â ÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í¿Í °á·Ð

Á¦2Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå : Á¤ÀÇ ¹× Á¶»ç ÀüÁ¦

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ÀüÁ¦
    • Æ÷ÇÔ ¹× Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ½ÃÀå °æÀï
      • °æÁ¦Àû ½ÇÇö °¡´É¼º(»ý»êÀÚÀÇ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ Ʋ
      • ±â¼úÀû Áøº¸
      • µ¿¹°º¹Áö¿¡ ´ëÇÑ ¹è·Á
      • ³ó°¡ÀÇ ÀÇ½Ä Çâ»ó°ú º¸±Þ
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó ¿¬µµ
  • ȯÀ² º¯È¯À²

Á¦3Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ý»ê¼º Çâ»ó¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡¿Í Á¡ÇÁ·Î ÀÎÇÑ °æÁ¦Àû ¼Õ½Ç
    • µ¿¹° º¹Áö¿¡ ´ëÇÑ ±â´ë Áõ°¡¿Í ±ÔÁ¦ ¾Ð·Â
    • °í±Þ Áø´Ü ±â¼ú(º¸Çà Á¡¼ö, ¿­È­»ó, AI)ÀÇ ÅëÇÕ
  • ½ÃÀåÀÇ °úÁ¦
    • ¼Ò±Ô¸ð ³ó°¡¿Í Áß±Ô¸ð ³ó°¡ÀÇ ³·Àº ÀǽÄ
    • °ËÃâ ÇÁ·Î±×·¥ÀÇ Àϰü¼ºÀÌ ¾ø´Â ½Ç½Ã
    • °³¹ß µµ»ó Áö¿ªÀÇ ½Ç½Ã°£ °¨½Ã ÀÎÇÁ¶ó ºÎÁ·
    • ÀÓ»ó ½ºÄھ ÇÁ·ÎÅäÄÝÀÇ Ç¥ÁØÈ­°¡ ºÒÃæºÐ
  • ½ÃÀå ±âȸ
    • ¸ð¹ÙÀϰú AI¸¦ Ȱ¿ëÇÑ ¿ø°Ý °¨½Ã ¿ëµµ
    • ÀÚµ¿È­¿Í µðÁöÅÐÈ­¸¦ ÅëÇÑ Á¢±Ù¼º°ú Àú·ÅÇÑ °¡°Ý È®´ë
    • ¿¹¹æÀûÀÎ ¹«¸®ÀÇ °Ç°­ °ü¸®·ÎÀÇ ÀÌÇà
    • °ü¹Î ÆÄÆ®³Ê½Ê°ú ±³À° Ä·ÆäÀÎ

Á¦4Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • PORTERS MODEL¿¡ ¹Ì·¡Àû Á¢±Ù
    • ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • Çõ½ÅÀÇ µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í¿Í °á·Ð

Á¦5Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ºÎ¹®º°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • °ø°ø ºÎ¹®ÀÇ ¼öÀÔ µ¿Ç⠺м®(2022³â, 2032³â)
  • ¹Î°£ ºÎ¹®ÀÇ ¼öÀÔ µ¿Ç⠺м®(2022³â, 2032³â)

Á¦6Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¼­ºñ½º Á¦°ø¾÷üº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼öÀÇ º´¿ø/Ŭ¸®´Ð °Ë»ç½Ç ¼öÀÍ µ¿Ç⠺м®(2022³â, 2032³â)

Á¦7Àå ¼¼°èÀÇ µÅÁö ÆÄÇà Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°(2022-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
    • IDEXX Laboratories, Inc.
    • Boehringer Ingelheim International GmbH
    • Merck Animal Health
  • ÁÖ¿ä ½ÃÀåÀÇ Àü·«
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • IDEXX Laboratories, Inc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¸§)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Boehringer Ingelheim International GmbH
    • Merck Animal Health
    • Thermo Fisher Scientific Inc.
    • Vetoquinol SA
    • Zoetis Inc.
    • Virbac
    • Elanco Animal Health
    • Neogen Corporation
    • Bimeda Animal Health
    • BioChek BV
    • Randox Laboratories Ltd.
    • BioNote Inc.
    • Biogal Galed Labs
    • HIPRA SA

Á¦9Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ¿¹Ãø
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»çÀÇ ¼Ó¼º
KTH 25.06.10

Global Swine Lameness Diagnostic Market is valued at approximately USD 0.12 billion in 2023 and is anticipated to grow with a moderate CAGR of more than 3.80% over the forecast period 2024-2032. As the global swine industry grapples with increasing productivity demands and animal welfare expectations, lameness in pigs has emerged as both an economic and ethical concern. Lameness not only compromises herd performance and reproductive efficiency but also results in premature culling and decreased carcass value. Swine lameness diagnostic tools, therefore, have become critical in early identification, treatment planning, and herd management optimization. These diagnostics are especially essential in intensive production settings where subclinical lameness often goes unnoticed without structured diagnostic approaches.

Modern veterinary diagnostic protocols are evolving rapidly, and the swine segment is no exception. Advanced gait-scoring systems, thermographic imaging, force plate technologies, and biochemical markers are now being integrated into lameness assessments. With public and private veterinary sectors emphasizing early and accurate detection, diagnostic services are being streamlined through collaboration with veterinary hospitals and clinic laboratories. These providers are playing a pivotal role in promoting timely interventions that reduce animal suffering, limit economic losses, and ensure regulatory compliance in export-driven pork markets.

The market's expansion, however, is curtailed by several operational bottlenecks. Low awareness among smallholder farmers, inconsistent implementation of lameness detection programs, and a lack of real-time monitoring infrastructure, particularly in developing economies, pose significant barriers to growth. Additionally, limited standardization in clinical scoring and diagnostic protocols affects the repeatability of diagnoses. Yet, the industry is steadily countering these constraints through mobile veterinary units, continuing education campaigns, and pilot programs in high-density pig farming regions aimed at spreading awareness about diagnostic best practices.

Technological advancements are injecting new life into this niche diagnostic sector. The development of mobile apps with integrated image analysis and AI-driven lameness scoring platforms is enabling remote monitoring and improving the precision of assessments. Furthermore, automation and digitization are expanding accessibility in previously underserved markets, making diagnostics more affordable and scalable. These innovations are fostering a gradual shift toward preventive herd health management rather than reactive treatment, especially in large-scale commercial farms.

Regionally, North America is expected to retain a substantial share of the global swine lameness diagnostic market owing to advanced veterinary infrastructure, a highly organized pork production industry, and strong public-private cooperation in animal health research. Europe trails closely, led by progressive animal welfare legislation and robust investments in herd monitoring technologies. The Asia Pacific region is set to grow at the fastest pace during the forecast period, fueled by expanding pork demand, growing awareness of productivity-linked animal health, and government-supported swine disease control programs in countries such as China, India, and Vietnam. Latin America and the Middle East & Africa are steadily emerging with rising commercialization of swine production and the adoption of basic diagnostic frameworks.

Major market player included in this report are:

  • IDEXX Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Merck Animal Health
  • Thermo Fisher Scientific Inc.
  • Vetoquinol S.A.
  • Zoetis Inc.
  • Virbac
  • Elanco Animal Health
  • Neogen Corporation
  • Bimeda Animal Health
  • BioChek B.V.
  • Randox Laboratories Ltd.
  • BioNote Inc.
  • Biogal Galed Labs
  • HIPRA S.A.

The detailed segments and sub-segment of the market are explained below:

By Sector

  • Public
  • Private

By Service Provider

  • Veterinary Hospital/Clinic Laboratories

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Years considered for the study are as follows:

  • Historical Year - 2022
  • Base Year - 2023
  • Forecast Period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with country-level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Swine Lameness Diagnostic Market Executive Summary

  • 1.1. Global Swine Lameness Diagnostic Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Sector (Public, Private)
    • 1.3.2. By Service Provider (Veterinary Hospital/Clinic Laboratories)
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Swine Lameness Diagnostic Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Producer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Animal Welfare Considerations
      • 2.3.4.4. Farmer Awareness & Adoption
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Swine Lameness Diagnostic Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising Productivity Demands and Economic Losses from Lameness
    • 3.1.2. Heightened Animal Welfare Expectations and Regulatory Pressure
    • 3.1.3. Integration of Advanced Diagnostic Technologies (Gait Scoring, Thermography, AI)
  • 3.2. Market Challenges
    • 3.2.1. Low Awareness among Smallholder and Mid-scale Farmers
    • 3.2.2. Inconsistent Implementation of Detection Programs
    • 3.2.3. Lack of Real-time Monitoring Infrastructure in Developing Regions
    • 3.2.4. Limited Standardization of Clinical Scoring Protocols
  • 3.3. Market Opportunities
    • 3.3.1. Mobile and AI-driven Remote Monitoring Applications
    • 3.3.2. Automation and Digitization to Expand Accessibility and Affordability
    • 3.3.3. Shift toward Preventive Herd Health Management
    • 3.3.4. Public-Private Partnerships and Education Campaigns

Chapter 4. Global Swine Lameness Diagnostic Market Industry Analysis

  • 4.1. Porter's Five Forces Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's Model
    • 4.1.7. Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economic
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunities
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspectives
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Swine Lameness Diagnostic Market Size & Forecasts by Sector (2022-2032)

  • 5.1. Segment Dashboard
  • 5.2. Public Sector Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.3. Private Sector Revenue Trend Analysis, 2022 & 2032 (USD Billion)

Chapter 6. Global Swine Lameness Diagnostic Market Size & Forecasts by Service Provider (2022-2032)

  • 6.1. Segment Dashboard
  • 6.2. Veterinary Hospital/Clinic Laboratories Revenue Trend Analysis, 2022 & 2032 (USD Billion)

Chapter 7. Global Swine Lameness Diagnostic Market Size & Forecasts by Region (2022-2032)

  • 7.1. North America
    • 7.1.1. U.S.
    • 7.1.2. Canada
  • 7.2. Europe
    • 7.2.1. UK
    • 7.2.2. Germany
    • 7.2.3. France
    • 7.2.4. Spain
    • 7.2.5. Italy
    • 7.2.6. Rest of Europe
  • 7.3. Asia Pacific
    • 7.3.1. China
    • 7.3.2. India
    • 7.3.3. Japan
    • 7.3.4. Australia
    • 7.3.5. South Korea
    • 7.3.6. Rest of Asia Pacific
  • 7.4. Latin America
    • 7.4.1. Brazil
    • 7.4.2. Mexico
  • 7.5. Middle East & Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. South Africa
    • 7.5.3. Rest of Middle East & Africa

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. IDEXX Laboratories, Inc.
    • 8.1.2. Boehringer Ingelheim International GmbH
    • 8.1.3. Merck Animal Health
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. IDEXX Laboratories, Inc.
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Market Strategies
    • 8.3.2. Boehringer Ingelheim International GmbH
    • 8.3.3. Merck Animal Health
    • 8.3.4. Thermo Fisher Scientific Inc.
    • 8.3.5. Vetoquinol S.A.
    • 8.3.6. Zoetis Inc.
    • 8.3.7. Virbac
    • 8.3.8. Elanco Animal Health
    • 8.3.9. Neogen Corporation
    • 8.3.10. Bimeda Animal Health
    • 8.3.11. BioChek B.V.
    • 8.3.12. Randox Laboratories Ltd.
    • 8.3.13. BioNote Inc.
    • 8.3.14. Biogal Galed Labs
    • 8.3.15. HIPRA S.A.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦